{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T21:02:18Z","timestamp":1792875738716,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.neuropharm.2015.10.024","type":"journal-article","created":{"date-parts":[[2015,10,25]],"date-time":"2015-10-25T21:25:15Z","timestamp":1445808315000},"page":"480-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"special_numbering":"C","title":["Neuroprotective effects of ginsenoside Rg1 through the Wnt\/\u03b2-catenin signaling pathway in both in\u00a0vivo and in\u00a0vitro models of Parkinson's disease"],"prefix":"10.1016","volume":"101","author":[{"given":"Tingting","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanhua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2015.10.024_bib1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.bbamcr.2003.10.013","article-title":"Bcl-2 family regulation of neuronal development and neurodegeneration","volume":"1644","author":"Akhtar","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2015.10.024_bib2","doi-asserted-by":"crossref","first-page":"E602","DOI":"10.1073\/pnas.1208524110","article-title":"Wnt5a cooperates with canonical Wnts to generate midbrain dopaminergic neurons in\u00a0vivo and in stem cells","volume":"110","author":"Andersson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.nbd.2014.11.007","article-title":"Ginsenoside Rb1 inhibits fibrillation and toxicity of alpha-synuclein and disaggregates preformed fibrils","volume":"74","author":"Ardah","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib4","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/jmcb\/mju001","article-title":"Wnt signaling in midbrain dopaminergic neuron development and regenerative medicine for Parkinson's disease","volume":"6","author":"Arenas","year":"2014","journal-title":"J.\u00a0Mol. Cell Biol."},{"issue":"Pt A","key":"10.1016\/j.neuropharm.2015.10.024_bib5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neuropharm.2013.08.035","article-title":"Parkinson's disease in a dish \u2013 using stem cells as a molecular tool","volume":"76","author":"Badger","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.10.024_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000092086","article-title":"Function of Wnts in dopaminergic neuron development","volume":"3","author":"Castelo-Branco","year":"2006","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib7","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1242\/jcs.01505","article-title":"GSK-3beta inhibition\/beta-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons","volume":"117","author":"Castelo-Branco","year":"2004","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib8","doi-asserted-by":"crossref","first-page":"12747","DOI":"10.1073\/pnas.1534900100","article-title":"Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a","volume":"100","author":"Castelo-Branco","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib9","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jnr.23138","article-title":"Brain-derived neurotrophic factor stimulates proliferation and differentiation of neural stem cells, possibly by triggering the Wnt\/\u03b2-catenin signaling pathway","volume":"91","author":"Chen","year":"2013","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib10","first-page":"829","article-title":"Protective effect of ginsenoside Rg1 against MPTP-induced apoptosis in mouse substantia nigra neurons","volume":"23","author":"Chen","year":"2002","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1745-7254.2005.00019.x","article-title":"Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress","volume":"26","author":"Chen","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0014-2999(03)01945-9","article-title":"Ginsenoside Rg1 attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress","volume":"473","author":"Chen","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","article-title":"Wnt\/beta-catenin signaling in development and disease","volume":"127","author":"Clevers","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2015.10.024_bib14","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","article-title":"Wnt\/\u03b2-catenin signaling and disease","volume":"149","author":"Clevers","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2015.10.024_bib15","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neuropharm.2012.10.031","article-title":"Induction of Dickkopf-1 contributes to the neurotoxicity of MPP+ in PC12 cells via inhibition of the canonical Wnt signaling pathway","volume":"67","author":"Dun","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.10.024_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0378-4274(02)00428-9","article-title":"Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease","volume":"139","author":"Eberhardt","year":"2003","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neuroscience.2011.02.027","article-title":"Dopaminergic and behavioral correlates of progressive lesioning of the nigrostriatal pathway with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"180","author":"Goldberg","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2015.10.024_bib18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11481-014-9569-6","article-title":"Potential neuroprotective activity of Ginseng in Parkinson's disease: a review","volume":"10","author":"Gonz\u00e1lez-Burgos","year":"2015","journal-title":"J.\u00a0Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jmcb\/mju002","article-title":"Regulating Wnt signaling: a strategy to prevent neurodegeneration and induce regeneration","volume":"6","author":"Harvey","year":"2014","journal-title":"J.\u00a0Mol. Cell Biol."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrn2755","article-title":"Emerging roles of Wnts in the adult nervous system","volume":"11","author":"Inestrosa","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/0197-0186(94)90017-5","article-title":"1-Methyl-4-phenylpyridinium (MPP+)-induced cell death in PC12 cells: inhibitory effects of several drugs","volume":"25","author":"Itano","year":"1994","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nprot.2006.342","article-title":"Protocol for the MPTP mouse model of Parkinson's disease","volume":"2","author":"Jackson-Lewis","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib23","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1212\/WNL.66.10_suppl_4.S24","article-title":"The pathogenesis of cell death in Parkinson's disease","volume":"66","author":"Jenner","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2015.10.024_bib24","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1212\/WNL.0b013e3182703f76","article-title":"Bid signal pathway components are identified in the temporal cortex with Parkinson disease","volume":"79","author":"Jiang","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2015.10.024_bib25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.nbd.2010.10.023","article-title":"Reactive astrocytes and Wnt\/\u03b2-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease","volume":"41","author":"L'Episcopo","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib26","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1523\/JNEUROSCI.5259-11.2012","volume":"32","author":"L'Episcopo","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib27","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/stem.1708","article-title":"Wnt\/\u03b2-catenin signaling is required to rescue midbrain dopaminergic progenitors and promote neurorepair in ageing mouse model of Parkinson's disease","volume":"32","author":"L'Episcopo","year":"2014","journal-title":"Stem Cells"},{"key":"10.1016\/j.neuropharm.2015.10.024_bib28","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","article-title":"Parkinson's disease","volume":"373","author":"Lees","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2015.10.024_bib30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/beta-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev. Cell"},{"key":"10.1016\/j.neuropharm.2015.10.024_bib31","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/ejn.12166","article-title":"Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt\/\u03b2-catenin signaling cascade as the common final pathway for neuroprotection and self-repair","volume":"37","author":"Marchetti","year":"2013","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0165-0270(96)02211-X","article-title":"Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion","volume":"73","author":"Matsuura","year":"1997","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2015.10.024_bib33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrg1427","article-title":"WNT and beta-catenin signalling: diseases and therapies","volume":"5","author":"Moon","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib34","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1527-3458.2007.00023.x","article-title":"Ginsenosides: are any of them candidates for drugs acting on the central nervous system?","volume":"13","author":"Nah","year":"2007","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0892-0362(02)00213-1","article-title":"Apoptotic molecules and MPTP-induced cell death","volume":"24","author":"Nicotra","year":"2002","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ana.24011","article-title":"Therapeutic prospects for Parkinson disease","volume":"74","author":"Olanow","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib37","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/jmcb\/mjt045","article-title":"Modulating Wnt signaling to improve cell replacement therapy for Parkinson's disease","volume":"6","author":"Parish","year":"2014","journal-title":"J.\u00a0Mol. Cell Biol."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib38","first-page":"135","article-title":"The parkinsonian toxin MPTP: action and mechanism","volume":"16","author":"Przedborski","year":"2000","journal-title":"Restor. Neurol. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1254\/jphs.CRJ05010X","article-title":"Use of ginseng in medicine with emphasis on neurodegenerative disorders","volume":"100","author":"Radad","year":"2006","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.brainres.2004.06.030","article-title":"Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate","volume":"1021","author":"Radad","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib41","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1755-5949.2010.00208.x","article-title":"Ginsenosides and their CNS targets","volume":"17","author":"Radad","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib42","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1212\/WNL.0b013e3181990438","article-title":"Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease","volume":"72","author":"Schapira","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2015.10.024_bib43","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.neuroscience.2015.04.069","article-title":"Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease","volume":"23","author":"Sconce","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2015.10.024_bib44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.brainres.2012.12.015","article-title":"Estrogen regulation of Dkk1 and Wnt\/\u03b2-Catenin signaling in neurodegenerative disease","volume":"1514","author":"Scott","year":"2013","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0166-4328(01)00309-6","article-title":"Behavioral phenotyping of the MPTP mouse model of Parkinson's disease","volume":"125","author":"Sedelis","year":"2001","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib46","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1179\/016164107X159144","article-title":"NMDA receptor and iNOS are involved in the effects of ginsenoside Rg1 on hippocampal neurogenesis in ischemic gerbils","volume":"29","author":"Shen","year":"2007","journal-title":"Neurol. Res."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib47","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1534-5807(03)00266-1","article-title":"A\u00a0second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling","volume":"5","author":"Veeman","year":"2003","journal-title":"Dev. Cell"},{"key":"10.1016\/j.neuropharm.2015.10.024_bib48","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1358\/dnp.2004.17.10.873916","article-title":"JNK inhibition as a potential strategy in treating Parkinson's disease","volume":"17","author":"Wang","year":"2004","journal-title":"Drug News Perspect."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib49","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/j.1476-5381.2009.00361.x","article-title":"Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway","volume":"158","author":"Xu","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.10.024_bib50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/WNR.0b013e32831c50df","article-title":"Molecular basis of Parkinson's disease","volume":"20","author":"Yang","year":"2009","journal-title":"Neuroreport"}],"updated-by":[{"DOI":"10.1016\/j.neuropharm.2024.110260","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000}}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390815301477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390815301477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T13:10:01Z","timestamp":1751029801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390815301477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":49,"alternative-id":["S0028390815301477"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.10.024","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroprotective effects of ginsenoside Rg1 through the Wnt\/\u03b2-catenin signaling pathway in both in\u00a0vivo and in\u00a0vitro models of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}